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doi:10.1Background: Patients on dialysis sustain at least a threefold higher in-hospital mortality rate andmarkedly higher
long-term mortality following coronary artery bypass graft surgery than the general population. Smaller studies
have suggested that dialysis patients have superior outcomes with off-pump compared with on-pump coronary
artery bypass surgery.
Methods: From the United States Renal Data System database, 13,085 patients on dialysis having first coronary
artery bypass surgery between 2001 and 2006 were identified. Of these, 2335 (17.8%) had off-pump coronary ar-
tery bypass surgery. The Kaplan-Meier method was used to estimate survival of patients having off-pump coronary
artery bypass and patients having on-pump coronary artery bypass. A Cox proportional hazards model was used to
assess effects of off-pump coronary artery bypass on mortality with adjustment for baseline patient characteristics.
Results: Off-pump coronary artery bypass surgery was associated with significantly reduced all-cause mortality
compared with on-pump coronary artery bypass surgery (hazard ratio 0.92, 95% confidence interval 0.86–0.99,
P¼ .02). The observed survival benefit was most notable in the first year after surgery (70.3% vs 68.7%) and was
lost 2 years after surgery (55.4% vs 55.2%). No difference was noted in the in-hospital mortality rate with off-
pump coronary artery bypass surgery versus on-pump coronary artery bypass surgery (9.7% vs 11.0%, P¼ .06).
Cardiac mortality during the follow-up period was similar (23.6% vs 23.8%; adjusted hazard ratio 0.95, 95%
confidence interval 0.86–1.04, P ¼ .26). Use of internal thoracic grafts was independently associated with im-
proved survival after coronary artery bypass surgery (hazard ratio, 0.92; 95% confidence interval, 0.87–0.98,
P ¼ .0057).
Conclusions: Patients on dialysis sustain high in-hospital and 2-year mortality rates after coronary artery bypass
surgery. Off-pump coronary artery bypass is associated with modestly increased survival compared with on-
pump coronary artery bypass, a benefit most marked early after off-pump coronary artery bypass. (J Thorac
Cardiovasc Surg 2010;139:1333-8)Patients with chronic kidney disease (CKD) are at markedly
high risk for cardiovascular morbidity and mortality. Esti-
mated glomerular filtration rate is strongly, inversely, and in-
dependently related to all-cause mortality, cardiovascular
events, and rates of hospitalization.1 Patients with CKD
who have percutaneous and surgical coronary revasculariza-
tion sustain markedly higher long-term all-cause mortality
than patients without CKD.2 One-year mortality for general
Medicare patients without CKD who had coronary artery
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M22% for patients with CKD without end-stage renal disease
(ESRD).3 In comparison, 1-year mortality for patients on
dialysis was 33%.4 Thus, mortality risk increases as renal
insufficiency worsens.
Off-pump coronary artery bypass (OPCAB) surgery is po-
tentially attractive for patients likely to have severe vasculop-
athy, such as patients with ESRD. Its principal physiologic
advantages over on-pump CABG surgery include the ability
to avoid the deleterious consequences of the systemic inflam-
matory response incited by the bypass circuit5 and atheroemb-
olism caused by aortic cannulation and crossclamping.6
Unfortunately, available literature regarding translating
these physiologic advantages into improved clinical out-
comes has been contradictory. The mortality benefit with
OPCAB noted in larger registry data7,8 has not been repro-
duced in smaller, randomized trials.9,10 In particular, no sur-
vival advantage with OPCAB has been shown for low-risk
patients.10 This inconsistency in the literature raises the
question of whether high-risk patients may benefit from
OPCAB but may have been underrepresented in previous
studies. Indeed, some studies suggest greater benefit of
OPCAB for high-risk patients, especially elderly patients
or patients with diabetes, previous stroke, or severe vascular
disease, and patients having repeat CABG.7,8,11,12diovascular Surgery c Volume 139, Number 5 1333
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MAbbreviations and Acronyms34CABG ¼The Joucoronary artery bypass graftCI ¼ confidence interval
CKD ¼ chronic kidney disease
CMS ¼ Centers for Medicare & Medicaid
CPT ¼ Current Procedural Terminology
ESRD ¼ end-stage renal disease
ICD-9-CM ¼ International Classification of
Diseases, Ninth Edition, Clinical
ModificationOPCAB ¼ off-pump coronary artery bypass
PCI ¼ percutaneous coronary intervention
USRDS ¼ United States Renal Data SystemPatients on dialysis constitute a high-risk population, sus-
taining at least a threefold higher in-hospital mortality rate
and higher rates of nonfatal complications after CABG
than the general population.13 Historically, patients on
long-term dialysis have beenmodestly represented in studies
comparing OPCAB and on-pump CABG.7,9,12 Limited pub-
lished data for patients on dialysis suggest superior out-
comes with OPCAB.14,15 The objectives of this study
were to compare survival for patients on dialysis having OP-
CAB versus on-pump CABG and to determine predictors of
survival for patients on dialysis having CABG.
METHODS
Database and Patients
Data for this study are from the United States Renal Data System
(USRDS) database (n ¼ 1,910,161). The accuracy of these data has been
previously validated.16 Institutional review board approval was obtained.
Patients on dialysis who had first CABG (International Classification of
Diseases, Ninth Edition, Clinical Modification [ICD-9-CM] procedure
code 36.1) between January 1, 2001, and December 31, 2006, after renal re-
placement therapy initiation, were identified for study inclusion. Those who
had CABG without cardiopulmonary bypass (OPCAB) were further identi-
fied by Current Procedural Terminology (CPT) code 00566. To assess for
possible crossover from the OPCAB to the on-pump CABG arm, CPT
code 00562 (with pump oxygenator) was assessed during the hospitalization
for OPCAB surgery. Internal thoracic graft use and number of vessels by-
passed were identified by ICD-9-CM codes 36.15, 36.16, and 36.11-36.19.
All eligible patients had been diagnosed with ESRD at least 90 days be-
fore CABG, were aged 20 years on the date of surgery, and resided in the
50 US states, Washington DC, or the US territories. All patients had Medi-
care as primary payer. Patients having concomitant valve surgery or with
prior CABG were excluded from the analysis.
Patient baseline characteristics included demographic factors (age, sex,
race, ESRD duration, ESRD cause, dialysis modality, prior renal trans-
plant), surgical variables (year of surgery, number of vessels bypassed,
use of internal thoracic graft), length of hospital stay for the CABG surgery
admission, and comorbid conditions. Comorbid conditions were determined
from the Centers for Medicare &Medicaid (CMS) ESRDMedical Evidence
Report (formCMS-2728) andMedicare claims using a previously published
methodology17,18 and included acute myocardial infarction, congestive
heart failure, other cardiac conditions, cerebrovascular accident/transient is-
chemic attack, diabetes, dysrhythmias, chronic obstructive pulmonary dis-rnal of Thoracic and Cardiovascular Surease, gastrointestinal bleeding, liver disease, cancer, and peripheral
vascular disease.
The outcomes evaluated were all-cause mortality, a combined event of
second CABG and all-cause mortality, and cardiac mortality. Cardiac mor-
tality was determined using data derived from the ESRDDeath Notification
form (CMS-2746). Death ascribed to myocardial infarction, pericarditis (in-
cluding cardiac tamponade), atherosclerotic heart disease, cardiomyopathy,
cardiac arrhythmia, cardiac arrest (cause unknown), valvular heart disease,
pulmonary edema due to exogenous fluid, and congestive heart failure were
classified as being due to cardiac causes.2 For all-cause and cardiac mortal-
ity, patients were followed from the date of CABG to the earliest occurrence
of death, 3 years after first CABG, or December 31, 2006. For the combined
event of second CABG and all-cause mortality, patients were followed to
the earliest occurrence of second CABG, death, 3 years after first CABG,
or December 31, 2006. Patients were censored at renal transplant or loss
to follow-up.
Data Analysis
Baseline characteristics of the OPCAB and on-pump CABG study pop-
ulations were defined as categorical variables and presented as proportions.
Differences were tested using the chi-square test. Length of stay for the
CABG surgery admission was also presented as a continuous variable,
and the difference between the 2 study groups was tested using the 2-sample
t test. In-hospital mortality was determined for both groups and the differ-
ence was tested using the chi-square test. Survival was estimated by the
Kaplan-Meier method, and subgroup survival was compared by log-rank
test. A Cox proportional hazards model was used to assess the effect of OP-
CAB on mortality risk compared with on-pump CABG with adjustment for
patient baseline characteristics. All statistical analyses were performed us-
ing SAS for Windows, version 9 (SAS Institute Inc, Cary, NC).RESULTS
We identified 13,085 patients on dialysis (11,977 on he-
modialysis and 1108 on peritoneal dialysis) who had
CABG surgery during the study period. Of these, 2335
(17.8%) had OPCAB. For all-cause mortality, mean stan-
dard deviation follow-up time was 16.9  13.0 months for
patients having OPCAB and 17.1 13.3 months for patients
having on-pump CABG. Similar mean follow-up times were
observed for the combined event of second CABG and all-
cause mortality: 16.7 13.0 months for patients having OP-
CAB and 17.0  13.3 months for patients having on-pump
CABG. The median follow-up time for death was 14.84
months for both groups. The median follow-up time for
the combined event of death and second CABG was 14.57
months for patients having OPCAB and 14.61 months for
patients having on-pump CABG.
Of the 2335 patients having OPCAB, 1050 (45.0%) died,
552 (23.6%) died of cardiac disease, 32 (1.4%) had a second
CABG, and4.4%were censored for renal transplant and0.2%
for loss to follow-up. Of the 10,750 patients having on-pump
CABG, 4993 (46.5%) died, 2562 (23.8%) died of cardiac dis-
ease, 123 (1.1%) had a second CABG, and 5.6% were cen-
sored for renal transplant and 0.2% for loss to follow-up.
Patients having OPCAB were more likely than those hav-
ing on-pump CABG to be older and to have peripheral vas-
cular disease but not previous cerebrovascular accident/
transient ischemic attack (Table 1). Patients having OPCABgery c May 2010
TABLE 1. Baseline characteristics of the study population
Coronary artery
bypass graft surgery
All On-pump Off-pump
Characteristics (n¼13,085) (n¼10,750) (n¼2335) P*
Age at surgery (y) <.0001
20–44 6.3 6.5 5.7
45–64 46.2 47.1 42.4
65–74 32.6 32.4 33.7
75 14.8 14.0 18.1
Sex .5588
Men 61.9 62.0 61.4
Women 38.1 38.0 38.6
Race .1169
White 65.4 65.6 64.8
African-American 28.0 28.1 27.8
Other 6.5 6.3 7.5
ESRD etiology .2502
Diabetes 57.6 57.7 56.9
Hypertension 24.0 23.7 25.3
Other 18.4 18.5 17.8
ESRD duration (y) .4517
<1 21.1 21.1 21.4
1–<3 33.1 33.2 32.3
3–<5 22.1 21.9 23.2
5 23.7 23.8 23.1
Prior transplant 5.6 5.7 5.0 .1813
Peritoneal dialysis 8.5 8.6 7.9 .2605
Year of surgery <.0001
2001 16.0 17.1 10.7
2002 17.6 18.0 16.2
2003 16.8 16.6 17.5
2004 17.3 16.8 19.9
2005 16.6 16.3 18.2
2006 15.6 15.2 17.5
LOS for surgery (d) .1013
<9 23.1 22.8 24.8
9–<12 21.6 21.5 22.1
12–<18 29.2 29.4 28.5
18 26.0 26.3 24.6
Number of vessels
bypassed
<.0001
1 7.8 6.3 14.3
2 19.7 18.0 27.2
3 36.7 37.1 34.6
4 35.9 38.5 23.8
Internal thoracic graft 76.5 75.5 81.0 <.0001
Comorbid conditions
AMI 53.9 54.2 52.4 .1083
Cancer 6.9 6.8 7.5 .1807
Cardiac, other 61.8 61.6 62.9 .2630
CHF 72.6 72.7 72.2 .6420
COPD 27.5 27.4 27.8 .7473
CVA/TIA 28.3 28.1 29.0 .4114
Diabetes 74.2 74.3 73.6 .4677
Dysrhythmia 54.1 53.9 55.1 .2909
TABLE 1. Continued
Coronary artery
bypass graft surgery
All On-pump Off-pump
Characteristics (n¼13,085) (n¼10,750) (n¼2335) P*
Gastrointestinal
bleeding
10.7 10.6 11.4 .2299
Liver disease 8.3 8.3 8.1 .7241
PVD 49.2 48.7 51.8 .0061
Values are percents unless otherwise indicated. AMI, Acute myocardial infarction;
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA,
cerebrovascular accident; TIA, transient ischemic attack; ESRD, end-stage renal dis-
ease; LOS, length of stay; PVD, peripheral vascular disease. *Using the chi-square test.
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patients having on-pump CABG. Interestingly, although in-
ternal thoracic graft use was high in both groups, it was
significantly higher for patients having OPCAB.
The number of patients having OPCAB increased pro-
gressively from 2001 to 2006, likely reflecting improved
operator expertise, more published literature and increased
awareness regarding OPCAB, and technological advances
in the field including development of mechanical stabiliza-
tion and cardiac positioning devices for OPCAB. The
mean length of stay during the CABG surgery hospitaliza-
tion was similar in both groups (15.32 days for OPCAB ver-
sus 15.73 days for on-pump CABG, P ¼ .17). The median
length of stay was 12 days in both study groups.
In-hospital mortality was 9.7% for patients having
OPCAB and 11.0% for patients having on-pump CABG
(P ¼ .06). Figure 1 presents the Kaplan-Meier curves for
all-cause survival for patients having OPCAB and patients
having on-pump CABG. The observed benefit of OPCAB
on all-cause survival was most notable in the first 12 months
after surgery. The estimated all-cause survival rates for
patients having OPCAB and patients having on-pump
CABG, respectively, were 90.4% versus 88.5%
(P ¼ .0087) at 30 days, 78.2% versus 76.5% (P ¼ .07) at
6 months, 70.3% versus 68.7% (P ¼ .10) at 1 year,
55.4% versus 55.2% at 2 years, and 42.1% versus 42.3%
at 3 years. After adjustment for baseline patient characteris-
tics, OPCAB was associated with an 8% reduction in death
compared with on-pump CABG (hazard ratio, 0.92; 95%
confidence interval [CI], 0.86–0.99; P ¼ .02).
When the combined event of second CABG and death
was examined via Cox proportional hazards model, OPCAB
continued to be associated with a statistically significant re-
duction in second CABG or death compared with on-pump
CABG (hazard ratio, 0.92; 95% CI, 0.86–0.98; P ¼ .01).
For the end point of second CABG alone, we found no dif-
ference between the 2 groups (P ¼ .22).
We also evaluated first claim for percutaneous coronary
intervention (PCI) after the admission for CABG surgery.
In the OPCAB group 103 patients (4.41%) and in thediovascular Surgery c Volume 139, Number 5 1335
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FIGURE 1. All-cause survival of patients on dialysis having off-pump and
on-pump coronary artery bypass surgery between 2001 and 2006. OPCAB,
Off-pump coronary artery bypass.
Perioperative Management Shroff et al
P
Mon-pump CABG group 346 patients (3.22%) had PCI dur-
ing the hospitalization for CABG surgery. Further analysis
of the timing of these procedures revealed that most pre-
ceded the CABG surgery. This finding likely reflects
CABG surgery occurring in the context of complicated or
unsuccessful PCI. In the OPCAB group 221 patients
(9.47%) and in the on-pump CABG group 876 patients
(8.15%) had PCI after the hospitalization for CABG surgery.
In the OPCAB group 123 patients (5.27%) had PCI within 1
year of the hospitalization and 98 patients (4.19%) after 1
year. In the on-pump CABG group 473 patients (4.4%)
had PCI within 1 year of the hospitalization and 403 patients
(3.75%) after 1 year. The distribution of timing of the first
PCI procedure relative to the hospitalization for CABG sur-
gery (during, within 1 year, and after 1 year) between groups
was statistically significant (P ¼ .0037).
Advanced age, diabetic ESRD, dialysis duration, perito-
neal dialysis, and cardiovascular comorbid conditions (con-
gestive heart failure, myocardial infarction, and peripheral
vascular disease) were identified as independent predictors
of all-cause mortality (Table 2). Consistent with prior publi-
cations on coronary revascularization, survival was better
for African-American patients on dialysis than for white
patients on dialysis.13 Interestingly, single-vessel CABG
versus multivessel CABG was noted to be an independent
predictor of mortality, perhaps reflecting incomplete revas-
cularization. Concordant with prior data on CABG in the
general population, use of internal thoracic grafts was asso-
ciated with an 8% reduction in mortality (hazard ratio, 0.92;
95% CI, 0.87–0.98; P ¼ .0057).
The adjusted hazards ratio of cardiac mortality for OP-
CAB versus on-pump CABG was 0.95 (95% CI, 0.86–
1.04; P ¼ .26).The observed benefit of OPCAB on cardiac
survival was most notable in the first 6 months after surgery1336 The Journal of Thoracic and Cardiovascular Surand diminished after 12 months. The estimated cardiac sur-
vival rates for patients having OPCAB and patients having
on-pump CABG, respectively, were 93.8% versus 92.4%
(P ¼ .02) at 30 days, 87.6% versus 86.3% (P ¼ .09) at 6
months, 82.6% versus 82.2% at 1 year, 73.4% versus
74.2% at 2 years, and 64.1% versus 65.5% at 3 years.
Of the 2335 patients having OPCAB, 110 (4.7%) had
claims with CPT code 00562 (with pump oxygenator) dur-
ing the same hospitalization, suggesting crossover to an
on-pump CABG procedure. The Kaplan-Meier survival es-
timates at 30 days for the crossover OPCAB group, the OP-
CAB-only group, and the on-pump CABG group were
88.1%, 90.5%, and 88.5% respectively (P value by log-
rank test ¼ .024). The survival advantage for the OPCAB-
only group was lost at 6 months after the surgery.
DISCUSSION
Patients on dialysis constitute an extremely high-risk pop-
ulation with respect to outcomes following CABG surgery;
Herzog and colleagues13 previously reported in-hospital
mortality of 8.6% and 2-year mortality of 44%. Using the
Society of Thoracic Surgeons database, Cooper and associ-
ates19 noted an operative mortality rate of 9% for dialysis-
dependent patients having CABG surgery, with a marked
incremental increase in mortality with worsening glomerular
filtration rates. Due to the possible benefit of OPCAB for
high-risk populations, it is reasonable to evaluate its use in
patients on dialysis as a potential strategy to reduce mortality
associated with CABG. Manabe and coworkers20 suggested
a physiologic basis for supporting OPCAB in patients on
hemodialysis by demonstrating improved cardiac hemody-
namics in the form of postoperative reduction in right atrial
and pulmonary capillary wedge pressure and improvement
in postoperative lung oxygenation compared with patients
having on-pump CABG.
We found an 8% risk reduction in all-cause mortality as-
sociated with OPCAB in patients on dialysis. This modest
benefit was noted primarily in the first year after surgery,
likely reflecting the advantages of the surgical technique it-
self in preventing deleterious inflammatory, vascular, and
embolic consequences of cardiopulmonary bypass in vari-
ous organ beds,5,6 combined with a postulated favorable
early effect on cardiac hemodynamics.20 Because patients
on dialysis constitute an extremely high-risk population
with regard to operative and long-term mortality, this benefit
might be attenuated. The high rates of noncardiac mortality
we noted point to the complex noncardiac morbidity in this
population. This is further reflected by the longer hospital
stays for patients on dialysis despite OPCAB use in this
study, contrary to observations from previous studies in
the general population.
Few studies have previously assessed the impact of OP-
CAB on mortality in patients on dialysis.14,15,21-23 Dewey
and colleagues14 studied 158 patients on hemodialysis;gery c May 2010
TABLE 2. Cox proportional hazards model for independent
predictors of all-cause mortality in patients on dialysis having
coronary artery bypass graft surgery
Characteristics Hazard ratio (95% CI)* P
Off-pump CABG surgery 0.92 (0.86–0.99) .018
Age at surgery (y)
20–44 0.89 (0.79–1.02) .085
65–74 1.27 (1.20–1.35) <.0001
75 1.67 (1.55–1.80) <.0001
Sex
Women 1.13 (1.07–1.19) <.0001
Race
African-American 0.88 (0.83–0.94) <.0001
Other race 0.96 (0.86–1.07) .4179
ESRD duration (y)
<1 0.86 (0.79–0.92) <.0001
3–<5 1.21 (1.13–1.29) <.0001
5 1.35 (1.25–1.45) <.0001
ESRD etiology
Diabetes 1.24 (1.13–1.35) <.0001
Hypertension 1.14 (1.05–1.23) .0021
Prior transplant 0.97 (0.85–1.11) .6515
Peritoneal dialysis 1.47 (1.35–1.61) <.0001
Year of surgery
2001 1.17 (1.04–1.32) .007
2002 1.16 (1.03–1.29) .0128
2003 1.08 (0.97–1.21) .1757
2004 1.06 (0.95–1.19) .2940
2005 1.08 (0.96–1.22) .1991
Internal thoracic graft 0.92 (0.87–0.98) .0057
Number of vessels bypassed
1 1.29 (1.18–1.42) <.0001
2 1.16 (1.08–1.24) <.0001
3 1.02 (0.96–1.08) .6184
LOS for surgery (d)
9–<12 0.88 (0.81–0.95) .0023
12–<18 0.94 (0.87–1.01) .0999
18 1.37 (1.27–1.48) <.0001
Comorbid conditions
AMI 1.24 (1.17–1.30) <.0001
Cancer 1.07 (0.97–1.17) .1771
Cardiac, other 1.15 (1.08–1.21) <.0001
CHF 1.30 (1.21–1.39) <.0001
COPD 1.24 (1.17–1.31) <.0001
CVA/TIA 1.23 (1.16–1.29) <.0001
Diabetes 1.06 (0.97–1.14) .1874
Dysrhythmia 1.41 (1.33–1.49) <.0001
Gastrointestinal bleeding 1.15 (1.07–1.24) .0002
Liver disease 1.20 (1.10–1.31) <.0001
PVD 1.32 (1.25–1.39) <.0001
AMI,Acute myocardial infarction; CABG, coronary artery bypass graft; CHF, conges-
tive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary dis-
ease; CVA, cerebrovascular accident; TIA, transient ischemic attack; ESRD, end-stage
renal disease; LOS, length of stay; PVD, peripheral vascular disease. *Reference
groups: ages 45–64 years, men, white race, other cause of ESRD, ESRD duration
1–<3 years, no prior transplantation, hemodialysis modality, year of surgery 2006,
no internal thoracic graft, 4 vessels bypassed, length of stay<9 d; no comorbid
conditions.
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fit with OPCAB, but it should be noted that the perioperative
mortality in their OPCAB group was extraordinarily low at
1.7% versus 17.2% for the on-pump CABG control group.
Beckermann and associates15 studied 3922 patients in the
USRDS database; 13.8% had OPCAB in a 2-year entry pe-
riod. The authors reported a 14% risk reduction in all-cause
mortality for the OPCAB group compared with the on-pump
CABG group, but the researchers did not assess the poten-
tially important effect of number of vessels bypassed. More-
over, the sample size in the current study is approximately
3 times larger, with length-of-stay information and more
recent patient data, compared with the study by Beckermann
and colleagues. 15
OPCAB may also confer short-term benefit in the general
population. Hannan and coworkers24 reported a significant
19% reduction in inpatient and 30-day mortality using
New York state registry data. In a meta-analysis of 14
non-randomized trials, Panesar and colleagues25 showed
a marked reduction in in-hospital mortality rates, especially
among octogenarians. In another meta-analysis, Wijeysun-
dera and colleagues26 found a short-term mortality advan-
tage in observational studies but not randomized studies.
Similar to our study, previous studies have demonstrated
that the early benefit of OPCAB disappears in the long term.
In a large retrospective study, Hannan and associates24
found that 3-year mortality rates with OPCAB were compa-
rable to on-pump CABG. Further, concerns have been raised
regarding OPCAB and the long-term adequacy of revascu-
larization.24,26,27 We found no significant difference in oc-
currence of second CABG for OPCAB versus on-pump
CABG. Reassuringly, we found no increase in mortality
for patients having OPCAB in longer follow-up.
Only 17.8% of our study group had OPCAB over 6 years,
less than the 25% to 30% OPCAB use in the general pop-
ulation in New York state.24,28 Although there has been
a slight interval increase in the percentage of patients on di-
alysis who now have OPCAB (17.8% in the current study vs
14% in 2001–2002),15 OPCAB is relatively underused in
this high-risk patient population compared with the general
population.
Our study has several limitations. The retrospective nature
of the evaluation introduces the possibility of selection bias.
The USRDS database consists predominantly of administra-
tive data. Clinical variables such as left ventricular ejection
fraction, functional class, coronary arteriographic data, and
degree of aortic calcification could not be studied. Previous
studies have reported a higher mortality rate following
a crossover or conversion from OPCAB to an on-pump
procedure.29 Thus, we attempted to assess the number of pa-
tients who crossed over, but the method we used may have
underestimated the crossover rate.
In summary, this study represents the largest number of
patients on long-term dialysis for whom OPCAB anddiovascular Surgery c Volume 139, Number 5 1337
Perioperative Management Shroff et al
P
Mon-pump CABG outcomes have been compared. Our find-
ings indicate that patients on dialysis are a high-risk popula-
tion and sustain very high in-hospital and 2-year mortality
rates. Patients on dialysis may benefit from OPCAB by re-
duced early mortality compared with on-pump CABG. Ran-
domized controlled trials are needed in this high-risk patient
population to ascertain the strength of this benefit. Based on
our observational data, OPCAB for patients on dialysis who
have CABG surgery may offer a modest benefit in outcome.
We thank United States Renal Data System colleagues Shane
Nygaard, BA, for manuscript preparation, and Nan Booth, MSW,
MPH, for manuscript editing.
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